profound neuromuscular blockade

PreclinicalSmall molecule

profound neuromuscular blockade is one of 4 small molecule programs targeting Neuromuscular Blockade. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuromuscular BlockadeUnknown status

Neuromuscular BlockadePreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in Neuromuscular Blockade

#DrugCompanyPhaseTrials

Arduan

OOrganon and Co

Approved

2 2

HRS-9190

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 3

Conventional Dose CRRT

SSeoul National University Hospital

Preclinical

1 4

profound neuromuscular blockade

SSheba Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuromuscular Blockade1 trial

Neuromuscular Blockade and Surgical Conditions

Unknown status·SSheba Medical Center·N/A·NCT01564576·40 enrolled

Pulmonary Function1 trial

Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function

Unknown status·YYing Xiao·Phase 4·NCT01804933·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for profound neuromuscular blockade. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — profound neuromuscular blockade compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for profound neuromuscular blockade. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheba Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSheba Medical Center

profound neuromuscular blockade

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuromuscular Blockade1 trial

Pulmonary Function1 trial

References

Drug Info

Quick Facts

Related News